NCT03646370View on ClinicalTrials.gov

Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen

CompletedOBSERVATIONAL
Enrollment

110

Participants

Timeline

Start Date

July 25, 2018

Primary Completion Date

July 24, 2019

Study Completion Date

July 24, 2019

Conditions
HIV-1-infectionMetabolic SyndromeCardiovascular DiseasesWeight GainRenal Function AbnormalHyperglycemia
Interventions
DRUG

Tenofovir Alafenamide

Patients with HIV infection who are virally suppressed receiving a tenofovir disoproxil fumarate-based antiretroviral therapy regimen that switched to tenofovir alafenamide without switching any other components of their treatment regimen.

Trial Locations (1)

19107

Thomas Jeffeson University, Philadelphia

All Listed Sponsors
lead

Thomas Jefferson University

OTHER

NCT03646370 - Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen | Biotech Hunter | Biotech Hunter